The purpose of this study was to find potential
biomarkers in the
serum of
patients with
depression and provide the basis for
clinical diagnosis of
depression. Sixteen
patients of severe
depression were selected according to the inclusion criteria and 16 healthy people were used in the
control group. The
depression patients took
paroxetine for two weeks. The
serum was collected from the
patients and healthy
control group before and after
paroxetine treatment. The samples were analyzed by
1H NMR based
metabolomics to determine the changes in profiles of endogenous metabolites and metabolites with significant differences were selected in
analysis. Related pathways and
receiver operating characteristic (ROC) were examined in
analysis of the correlation between the potential
biomarkers and
depression. Their feasibility and reliability was determined for the clinical practice. Significant differences were observed in the
metabolic profile of
serum of the
patients and the healthy controls.
Depression had an effect on
metabolism for an increase in
leucine,
isoleucine and
alanine,
glutamate,
glutamine and N-acetyl-
glycoprotein and a decrease in
glucose. Those may be considered as potential
biomarkers of
depression. Clinical application of the
biomarkers may improve the objectivity of the
diagnosis and
treatment of
depression by
antidepressant drugs. The
metabolomics approach is an effective tool in the investigation of
biomarkers.